¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"relative specific activity"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • relative metabolic rate
    »ó´ë´ë»çÀ²
  • relative motion
    »ó´ë¿îµ¿
  • relative odds
    »ó´ëÀû´ëÀÀºñ
  • relative refractory period
    »ó´ëºÒÀÀ±â
  • relative risk
    »ó´ëÀ§Çèµµ
  • relative risk ratio
    »ó´ëÀ§Çèºñ
  • relative scotoma
    »ó´ë¾ÏÁ¡
  • relative sterility
    »ó´ëÀûºÒÀÓ
  • relative survival rate
    »ó´ë»ýÁ¸À²
  • relative valvular insufficiency
    »ó´ëÀûÆÇ¸·±â´ÉºÎÀü
  • resource based relative value scale
    ÀÚ¿ø±âÁØ»ó´ë°¡Ä¡µî±Þ
  • spontaneous activity
    ÀÚ¹ßÀüÀ§
  • structure activity relationship
    ±¸Á¶È°¼º»ó°ü°ü°è, ±¸Á¶ÀÛ¿ë°ü°è
  • sexual activity
    ¼ºÈ°µ¿
  • age-specific death rate
    ¿¬·Éº°»ç¸Á·ü
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • relative flatness
    »ó´ëŹÀ½
  • relative frequency
    ºñ±³ºóµµ
  • haplodistinct relative
    ÀϹè¼öÀÌÁ¾°ü°è
  • haploidentical relative
    ÀϹè¼öµ¿Á¾°ü°è
  • relative hearing
    »ó´ëÀûû°¨
  • relative humidity
    »ó´ë½Àµµ
  • relative immunity
    »ó´ë¸é¿ª
  • relative incompetence
    »ó´ë¼ººÎÀü
  • relative valvular insufficiency
    »ó´ëÀûÆÇ¸·ºÎÁ·
  • relative leukocytosis
    ºñ±³¹éÇ÷±¸Áõ°¡Áõ
  • relative motion
    »ó´ë¿îµ¿
  • time dependent relative risk model
    ½Ã°£ÀÇÁ¸»ó´ëÀ§Çè¸ðµ¨
  • relative odds
    »ó´ëÀû´ëÀÀºñ
  • relative magnetic permeability
    »ó´ëÀÚ±âÅõ°ú·Â
  • relative refractory period
    »ó´ëºÒÀÀ±â
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • group-specific antigen
    ±º-ƯÀÌÇ׿ø
  • idiotype specific regulatory cell
    °³º°Æ¯ÀÌÇü Á¶Àý¼¼Æ÷
  • immunity, specific
    ƯÀ̸鿪
  • platelet-specific antigens
    Ç÷¼ÒÆÇƯÀÌÇ׿ø
  • pneumococcal [specific] polysaccharide
    Æó·Å±¸±Õ(ƯÀÌ)´Ù´ç·ù
  • polysaccharide, pneumococcal [specific]
    Æó·Å±¸±Õ(ƯÀÌ)´Ù´ç·ù
  • prostate specific antigen
    Àü¸³¼±Æ¯ÀÌÇ׿ø
  • prostate-specific antigen
    Àü¸³¼±Æ¯ÀÌÇ׿ø(îñí¡àÍ÷åì¶ù÷ê«)
  • prostatic specific antigen
    Àü¸³¼± ƯÀÌÇ׿ø
  • haplodistinct relative
    ÀϹè¼öÀÌÁ¾°ü°è<--ģô>
  • haploidentical relative
    ÀϹè¼öµ¿Á¾°ü°è<--ģô>
  • hearing, relative
    »ó´ëÀû û°¨
  • radiation,relative biologic effectiveness(rbe)
    »ó´ëÀû(ºñ±³Àû)»ý¹°ÇÐÀûÈ¿°ú(ßÓÓßîÜ(ÝïÎòîÜßæÚªùÊîÜüùÍý)
  • relative accommodation
    »ó´ëÁ¶Àý(ÝïÎòðàï½).
  • relative acidosis
    »ó´ëÀû »êÁõ(ßÓÓßîÜß«ñø).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • relative hepatic dullness
    »ó´ë°£Å¹À½°è(ßÓÓßÊÜöúëåÍ£)
  • relative humidity
    »ó´ë½Àµµ
  • relative immunity
    »ó´ë¸é¿ª(¡­Øóæ¹).
  • relative incompetence
    »ó´ë¼º ºÎÀü(¡­àõÝÕîï).
  • relative incompetence
    »ó´ë¼º ºÎÀü(ßÓÓßàõÝÕîï)
  • relative leukocytosis
    ºñ±³¹éÇ÷±¸Áõ°¡Áõ(ÝïÎòÛÜúìϹñòÊ¥ñø).
  • relative leukocytosis
    ºñ±³¹éÇ÷±¸Áõ°¡Áõ(ÝïÎòÛÜúìϹñòÊ¥ñø)
  • relative magnetic permeability
  • relative measurement
    ºñ±³ÃøÁ¤(ËÓË´Ì¬Ëø).
  • relative metabolic rate
    »ó´ëÀû ´ë»çÀ².
  • relative motion
    »ó´ë¿îµ¿(ßÓÓßê¡ÔÑ).
  • relative osteoid volume
    »ó´ëÀû À¯°ñ·®
  • relative polycythemia
    »ó´ëÀû ÀûÇ÷±¸Áõ°¡Áõ(ßÓÓßîÜîåúìϹñòÊ¥ñø).
  • relative polycythemia
    »ó´ëÀû ÀûÇ÷±¸Áõ°¡Áõ(ßÓÓßîÜîåúìϹñòÊ¥ñø)
  • relative refractory period
    »ó´ë(Àû) ºÒÀÀ±â(ßÓÓßîÜÝÕëëÑ¢).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • apparent specific volume
    ¿Ü°ß(èâ̸) ºñ(Ýï)¿ëÀû(é»îÝ)
  • enzyme-specific electrode
    È¿¼ÒƯÀÌ Àü±Ø (ý£áÈ÷åì¶ï³Ð¿)
  • organ specific enzyme
    ±â°üƯÀÌÈ¿¼Ò(Ðïί÷åì¶ý£áÈ)
  • partial specific quantity
    Æíºñ·®(ø¶ÝïÕá)
  • partial specific volume
    Æíºñ¿ëÀû(ø¶Ýïé»îÝ)
  • plasma-specific enzyme
    Ç÷À寝ÀÌ È¿¼Ò(úìíì÷åì¶ý£áÈ)
  • site-specific endonuclease
    ÀÚ¸® ƯÀ̼º(÷åì¶àõ) ¿£µµ´©Å¬¸®¿¡À̽º
  • site-specific inversion
    ÀÚ¸®Æ¯ÀÌ(÷åì¶) ¿ªÀ§(æ½êÈ)
  • site-specific recombinstion
    ÀÚ¸®Æ¯ÀÌ(÷åì¶) ÀçÁ¶ÇÕ(î¢ðÚùê)
  • specific acid-base catalysis
    ƯÀÌ »ê.¿°±â Ã˸Å(÷åì¶ß«ç¤ÐñõºØÚ)
  • specific adsorption
    ¼±ÅÃÈíÂø(àÔ÷Éýåó·)
  • specific dynamic action
    ƯÀÌ µ¿Àû ÀÛ¿ë(÷åì¶ÔÑîÜíÂéÄ)
  • specific extinction coefficient
    ºñÈí±¤ °è¼ö(ÝïýåÎÃÌõâ¦)
  • specific gravity
    ºñÁß(Ýïñì)
  • specific growth rate
    ºñ¼ºÀåÀ²(Ýïà÷íþëÒ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
SR sarcoplasmic reticulum; saturation recovery; scanning radiometer; screen; secretion rate; sedimentat...
TS Takayasu syndrome; Tay-Sachs; temperature sensitivity; temperature, skin; temporal stem; tensile str...
TSA technical surgical assistance; toluene sulfonic acid; total shoulder arthroplasty; total solute abso...
TSTA toxoplasmin skin test antigen; tumor-specific tissue antigen; tumor-specific transplantation antigen...
BGSA blood granulocyte-specific activity
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
RBE Relative Biological Efficiency
RBW Relative Body Weight
RDR Relative Dose Response
REM Relative Electrophoretic Mobility
RH Relative Humidity
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • specific region
    ƯÀÌ ºÎÀ§
  • specific tender point site
    ƯÁ¤ ¾ÐÅëÁ¡
  • specific weight
    ºñÁß
  • tumor specific transplantation
    Á¾¾ç ƯÀ̼º À̽Ä
  • virus-specific surface antigen
    ¹ÙÀÌ·¯½º ƯÀ̼º Ç¥¸é Ç׿ø ¹ÙÀÌ·¯½º
  • activity
    Ȱ¼ºµµ, Ȱµ¿µµ
    1. Ȱ¼ºÈ­µÈ »óÅÂ. ¾î¶² È¿°ú¸¦ ¾òÀ» ¼ö ÀÖ´Â ´É·Â. ¾î¶² ÀÛ¿ë ¶Ç´Â ±â´ÉÀÇ ¿¬Àå. 2. ºñÀÌ»óÀûÀÎ ¿ë¾×¿¡¼­ È¿°úÀûÀÎ ³óµµ¸¦ ³ªÅ¸³¾ ¼ö ÀÖ´Â ¿­¿ªÇÐÀûÀÎ ¾ç. ¸¸¾à ³óµµ°¡ Ȱµ¿µµ·Î ´ëü µÈ´Ù¸é ÆòÇü»ó¼ö¿¡ °üÇÑ ¹æÁ¤½Ä, ÀüÀ§, »ïÅõ¾Ð, ²ú´Â Á¡ ¿À¸§, ¾î´Â Á¡ ³»¸², Èֹ߼º ¿ëÁúÀÇ Áõ±â¾ÐÀº Èñ¼® ¿ë¾×¿¡¼­ ¸ðµç ³óµµ¿¡ ´ëÇØ °íÁ¤µÈ Á¤È®ÇÑ ¹æÁ¤½ÄÀÇ ±Ù»ç °ªÀ¸·Î ¹Ù²î¾î Áø´Ù. Ȱµ¿µµ´Â ºñÀÌ»óÀûÀÎ °ÍÀ¸·ÎºÎÅÍ ÃøÁ¤µÈ ºÎÇǰ¡ ¾ø´Â ¼ýÀÚ, Ȱµ¿°è¼ö¿Í »ý»ê¹°ÀÇ ³óµµ¿Í °°´Ù.
  • activity index
    Ȱµ¿ Áö¼ö
  • antibacterial activity
    Ç×±Õ ÀÛ¿ë
  • binding activity
    °áÇÕ È°¼º
  • bone activity
    °ñ Ȱ¼º
  • chemotactic activity
    È­ÇÐ ÁÖ¼º´É
  • concomitant activity
    µ¿¹Ý Ȱµ¿, ºÎ¼öÀû È¿°ú
  • diurnal activity
    ÁÖ°£ ÀÌ»ó ±â´É Ȱµ¿
  • efferent activity
    ¿ø½É Ȱ¼º
  • efferent sympathetic activity
    ¿ø½É ±³°¨½Å°æ Ȱ¼º
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
melanoma growth stimulatory activity Cytokine of the C X C subfamily. Potent mitogen. Activates and is chemotactic for, neutrophils.
(18 Nov 1997)
water activity <chemistry> An expression of the relative availability of water in a substance. Pure water has an water activity of 1.000. The water activity of a solution is one-hundredth its relative humidity.
(09 Oct 1997)
motor activity The physical activity of an organism as a behavioural phenomenon.
(12 Dec 1998)
complement haemolytic activity assay Usual screening assay for complement. Dilutions of the serum to be tested are added to antibody-coated erythrocytes and the percentage of lysis is measured. The values are expressed by ch50, haemolytic complement units per milliliter, which is the dilution of serum required to lyse 50 percent of the erythrocytes in the assay.
(12 Dec 1998)
plasma renin activity The estimation of renin in plasma by measuring the rate of formation of angiotensin I or II.
(05 Mar 2000)
solar activity Any type of variation in the appearance of energy output of the sun.
(12 Dec 1998)
structure activity analysis Study in which systematic variation in the structure of a compound is correlated with its activity, in an attempt to determine the characteristics of the (receptor) site at which it acts.
(18 Nov 1997)
structure-activity relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Other factors contributing to structure-activity relationship include chemical reactivity, electronic effects, resonance, and inductive effects.
(12 Dec 1998)
nonsuppressible insulin-like activity A blood protein (nsila) which mimics the biological activity of insulin in serum, but is not suppressed by insulin antibodies. During acid-ethanol extraction of cohn fraction III, 10% of the activity is found in the supernatant (nsila-s) and the remaining activity in the precipitate (nsila-p). The latter is a large molecular compound, much less stable than the soluble fraction. Nsila-s is a more potent growth factor than insulin and exhibits sulfation activity.
(12 Dec 1998)
drug activity A measure of the physiological response a drug produces. A less active drug produces less response (and visa versa).
(12 Dec 1998)
insulin-like activity A measure of substances, usually in plasma, that exert biologic effects similar to those of insulin in various bioassays; sometimes used as a measure of plasma insulin concentrations; always gives higher values than immunochemical techniques for the measurement of insulin.
(05 Mar 2000)
intrinsic sympathomimetic activity The property of a drug that causes activation of adrenergic receptors so as to produce effects similar to stimulation of the sympathetic nervous system.
(05 Mar 2000)
optical activity The ability of a material to rotate the plane of polarized light.
(09 Oct 1997)
triggered activity One or a series of spontaneously generated heart beats originating from an action potential that produces an after-depolarisation which reaches activation threshold.
(05 Mar 2000)
unit of thyrotrophic activity The activity of an amount of an extract of the anterior lobe of the hypophysis which, given daily for 5 days, will cause the thyroid of a guinea pig (weighing 200 g) to reach a weight of 600 mg.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á